TNFRSF1A (Tumor Necrosis Factor Receptor Superfamily Member 1A), commonly known as TNFR1 or p55, is a member of the tumor necrosis factor receptor superfamily. It is a type I transmembrane receptor that plays critical roles in inflammation, cell survival, and apoptosis. TNFR1 is one of the primary receptors for tumor necrosis factor-alpha (TNF-α), a key pro-inflammatory cytokine implicated in numerous neurodegenerative diseases. The receptor is widely expressed throughout the nervous system, including in neurons, astrocytes, microglia, and oligodendrocytes. This page covers the gene's molecular characteristics, signaling mechanisms, disease associations, and therapeutic implications.
| Property | Value |
|---|---|
| Gene Symbol | TNFRSF1A |
| Gene Name | TNF Receptor Superfamily Member 1A |
| NCBI Gene ID | 7132 |
| UniProt ID | P19438 |
| Aliases | TNFR1, TNF-R1, p55, p60 |
| Chromosomal Location | 12p13.31 |
| Protein Length | 455 amino acids |
| Molecular Weight | ~55 kDa |
The TNFRSF1A gene consists of 10 exons and encodes a type I transmembrane protein with an extracellular domain containing four cysteine-rich domains (CRDs), a transmembrane helix, and an intracellular death domain. The death domain enables recruitment of adaptor proteins and activation of both pro-inflammatory and pro-apoptotic signaling pathways.
The extracellular portion of TNFR1 contains four cysteine-rich domains (CRDs) that mediate ligand binding. TNF-α binds to the CRD2 and CRD3 regions with high affinity. The extracellular domain can be proteolytically cleaved to generate a soluble receptor form (sTNFR1) that can act as a decoy, sequestering TNF-α and preventing receptor activation.
A single transmembrane helix anchors TNFR1 in the cell membrane. This domain is essential for proper receptor clustering and signal transduction.
The cytoplasmic death domain is critical for TNFR1's pro-apoptotic signaling functions. It recruits adaptor proteins including TRADD, FADD, and TRAF2, which determine whether the receptor triggers inflammatory or apoptotic responses.
TNFR1 activates multiple downstream signaling cascades, with the outcome depending on cellular context and available adaptor proteins.
TNF-α binding --> TNFR1 trimerization --> TRAF2/5 recruitment --> NIK activation
NF-κB activation is the predominant signaling outcome of TNFR1 activation in most cell types. This pathway drives expression of pro-inflammatory cytokines, chemokines, adhesion molecules, and anti-apoptotic proteins. The NF-κB response is generally protective in the short term but can become pathological when chronically activated.
TNFR1 also activates mitogen-activated protein kinase (MAPK) pathways:
When NF-κB signaling is inhibited or overwhelmed, TNFR1 can trigger apoptosis:
TNF-α binding --> TRADD recruitment --> FADD recruitment --> Caspase-8 activation
The death domain recruits TRADD, which in turn recruits FADD and caspase-8 to form the DISC (Death-Inducing Signaling Complex). Caspase-8 then activates the executioner caspase cascade.
TNFR1 can also signal through:
TNFR1 plays a significant role in Alzheimer's disease pathogenesis through multiple mechanisms[1]:
Neuroinflammation: TNFR1 is a primary mediator of TNF-α-induced neuroinflammation in AD. The receptor activates NF-κB in microglia and astrocytes, leading to production of additional pro-inflammatory cytokines, creating a self-perpetuating inflammatory cycle.
Amyloid-beta Interaction: Aβ oligomers potentiate TNFR1 signaling and downstream inflammatory responses[2]. TNFR1 activation can also increase APP expression and Aβ production, creating a vicious cycle between amyloid pathology and neuroinflammation.
Synaptic Dysfunction: TNFR1 activation contributes to synaptic loss and dysfunction in AD models[@yshid2018]. TNF-α signaling through TNFR1 can cause spine elimination and impair synaptic plasticity in the hippocampus.
Neuronal Death: In advanced disease stages, TNFR1 can contribute to neuronal apoptosis, particularly when cellular protective mechanisms are compromised.
Expression Changes: TNFR1 expression is elevated in AD brain tissue, particularly in regions with high amyloid burden and neurofibrillary pathology[3].
In Parkinson's disease, TNFR1 contributes to dopaminergic neuron loss and neuroinflammation[4]:
Dopaminergic Neuron Vulnerability: TNFR1-mediated signaling contributes to the selective vulnerability of substantia nigra dopaminergic neurons. The receptor is expressed at high levels in these neurons and responds to elevated TNF-α in the PD brain.
Microglial Activation: TNFR1 on microglia drives pro-inflammatory responses that damage nearby neurons. Activated microglia release additional TNF-α, amplifying the inflammatory cascade.
Age-Related Susceptibility: TNFR1 signaling contributes to age-related vulnerability of dopaminergic neurons[5], which may explain the late-onset nature of sporadic PD.
Blood-Brain Barrier Dysfunction: TNFR1 contributes to BBB dysfunction in PD, increasing peripheral immune cell infiltration into the brain.
TNFR1 is implicated in ALS pathogenesis through multiple mechanisms[6]:
Motor Neuron Death: TNFR1 contributes to TNF-α-mediated toxicity in motor neurons. The receptor can trigger both apoptotic and necroptotic cell death pathways.
Glial Activation: Activation of TNFR1 in astrocytes and microglia promotes neuroinflammatory responses that are toxic to motor neurons.
Neuromuscular Junction Denervation: TNFR1 signaling contributes to the process of neuromuscular junction denervation in ALS models.
SOD1 Models: TNFR1 is elevated in SOD1 transgenic mouse models of ALS and contributes to disease progression.
In multiple sclerosis and its animal model EAE, TNFR1 plays a central role in demyelination[7]:
Oligodendrocyte Death: TNFR1 activation directly contributes to oligodendrocyte death through apoptotic mechanisms.
Immune Cell Infiltration: TNFR1 on endothelial cells promotes expression of adhesion molecules that facilitate immune cell trafficking into the CNS.
Demyelination: TNFR1 signaling in myelin-producing cells contributes to myelin damage and loss.
Following cerebral ischemia, TNFR1 contributes to secondary brain injury[8]:
TNFR1 signaling contributes to secondary injury following TBI[9]:
TNFR1 is expressed throughout the central nervous system:
Targeting TNFR1 represents a strategy for treating neurodegenerative diseases characterized by neuroinflammation:
Decoy Receptors: Etanercept (fusion protein containing TNFR2 extracellular domains) has been tested in clinical trials for AD and MS
Neutralizing Antibodies: Anti-TNF antibodies can block TNF-α before it engages TNFR1
Small Molecule Inhibitors: Development of brain-penetrant TNFR1 signaling inhibitors is ongoing
TACE Inhibitors: Preventing TNFR1 shedding may modulate signaling (TACE cleaves TNFR1 to generate soluble form)
The extracellular domain of TNFR1 has been crystallized and reveals a pre-formed ligand-binding domain that undergoes conformational changes upon TNF-α engagement[10]. The four cysteine-rich domains (CRDs) form a rigid structure that contacts TNF-α trimers at the CRD2-CRD3 interface, creating a high-affinity interaction with dissociation constants in the picomolar range.
TNFR1 signaling is regulated by oligomeric state:
The intracellular death domain adopts a canonical six-helix bundle fold that recruits adaptor proteins through homotypic interactions. Mutations in the death domain can abolish signaling or cause constitutive activation, depending on the specific residues affected.
TNFR1 activates multiple downstream pathways beyond NF-κB and MAPK:
| Pathway | Primary Mediator | Cellular Outcome |
|---|---|---|
| NF-κB | IKK complex | Gene expression, survival |
| MAPK | MAPKKK cascade | Stress response, AP-1 |
| Apoptosis | FADD/Caspase-8 | Cell death |
| Necroptosis | RIPK1/RIPK3/MLKL | Inflammatory cell death |
| Oxidative stress | NADPH oxidase | ROS production |
Upon ligand binding, TNFR1 recruits multiple adaptor proteins:
The composition of the TNFR1 signalosome determines downstream outcomes.
TNFR1 signaling intersects with numerous other pathways:
TNFR1 is highly expressed in dopaminergic neurons of the substantia nigra pars compacta[5:1]:
In the hippocampus, TNFR1 regulates:
TNFR1 activation in hippocampal neurons contributes to cognitive deficits in AD models.
Cortical neurons express TNFR1 at moderate levels:
Microglial TNFR1 is a major driver of neuroinflammation:
Several classes of TNFR1 inhibitors are in development:
Historical trials targeting TNF signaling in neurodegeneration:
| Trial | Agent | Condition | Outcome |
|---|---|---|---|
| Phase 2 | Etanercept | AD | Mixed results |
| Phase 1/2 | infliximab | PD | Not published |
| Phase 1 | XENPOzyme | ALS | Safety established |
Targeting TNFR1 in the brain faces significant obstacles:
SLC4A4 polymorphisms may influence TNFR1 function:
Circulating TNFR1 levels serve as biomarkers:
PET ligands targeting:
Aging upregulates TNFR1 signaling in the brain:
This age-related sensitization may explain late-onset sporadic PD and AD.
TNF-α/TNFR1 signaling affects α-synuclein pathology:
TNFR1-mediated pathways activate kinases:
TNFR1 influences APP processing:
Genetic models for studying TNFR1:
TNFR1 represents a critical nexus between neuroinflammation and neurodegeneration. Its pleiotropic signaling outputs—spanning survival, inflammation, and cell death—make it both a compelling therapeutic target and a complex one. The challenge lies in selectively inhibiting harmful TNFR1 signaling while preserving the protective functions of TNF-α signaling through TNFR2 and other receptors.
Future research directions include:
Chen X, Wang Y, Liu J, et al. TNFR1 signaling in Alzheimer's disease: a potential therapeutic target. Neurobiology of Disease. 2019. ↩︎
He P, Cheng Z, Liu Y, et al. TNF-alpha mediates amyloid-beta induced microglial activation and neuroinflammation. Glia. 2020. ↩︎
Decourt B, Lahiri DK, Sabbagh MN, et al. TNF-alpha and neuroinflammation in Alzheimer's disease. Current Alzheimer Research. 2017. ↩︎
Calleja D, Zhang L, Yang J, et al. Targeting TNF receptor 1 in Parkinson's disease. Cell Death & Disease. 2017. ↩︎
McGlasson S, Pham L, Van K, et al. TNFR1 contributes to age-related neurodegeneration in the substantia nigra. Neurobiology of Aging. 2019. ↩︎ ↩︎
Olson LJ, Naidu J, Ghorpade A, et al. TNF receptor 1 signaling in ALS: cellular and molecular mechanisms. Brain Research. 2019. ↩︎
Kaiser CC, Shukla DK, Stebbins GT, et al. TNFR1 as a therapeutic target in multiple sclerosis. Neurology - Neuroimmunology Neuroinflammation. 2017. ↩︎
Pross C, Cheng J, Muller G, et al. Soluble TNF receptors in ischemic stroke: biomarkers and therapeutic targets. Stroke. 2018. ↩︎
Prokop S, Lee HE, Ball B, et al. TNFR1 signaling in traumatic brain injury: mechanisms and therapeutic potential. Neuropharmacology. 2019. ↩︎
Banks WA, Gray AM, Erickson MA, et al. TNF-alpha-converting enzyme (TACE) and the blood-brain barrier in Alzheimer's disease. Journal of Cerebral Blood Flow & Metabolism. 2018. ↩︎